its specific inhibition by SST0001, a N-acetylated glycol-split heparin with a strong anti-HPSE activity. Rat mesothelial cells were grown for 6 days in HG (200 mM) culture medium with or without SST0001. Then EMT markers (VIM, a-SMA, TGF-b) and vascular endothelial growth factor (VEGF) (a factor involved in neoangiogenesis) were measured by real-time PCR and immunofluorescence/western blotting. As a functional analysis, trans-epithelial resistance (TER) and permeability to albumin were also measured in our in vitro model using a Millicell-ERS ohmmeter and a spectrophotometer, respectively. Results. Our results showed that 200 mM of glucose induced a significant gene and protein up-regulation of VEGF and all EMT markers after 6 days of culture. Intriguingly, adding SST0001 on day 3 reversed these biological and cellular effects. HPSE inhibition also restored the normal TER and permeability lost during the HG treatment.
Conclusion. Taken together, our data confirm that HG can induce EMT of mesothelial cells, and that HPSE plays a central part in this process. Our findings also suggest that pharmacological HPSE inhibition could prove a valuable therapeutic tool for minimizing fibrosis and avoiding a rapid decline in the efficacy of dialysis in patients on PD, though clinical studies and/or trials would be needed to confirm the clinical utility of this treatment.
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I N T R O D U C T I O N
Peritoneal dialysis (PD) is one of the available treatment options for patients with severe renal impairment (end-stage renal disease) and is valuable in young patients with a long life expectancy and good chances of undergoing renal transplantation [1] . In fact, PD affords more flexibility, allowing patients to continue working, it preserves their residual renal function, and it has less cardiovascular impact than haemodialysis (HD) [2] [3] [4] . On the other hand, it has been demonstrated in humans and animal models that the continuous contact with bioincompatible dialysis fluids (dialysates) during PD can induce significant morphological and functional changes in the peritoneum [e.g. progressive thickening of the submesothelium, narrowing and distortion of the vascular lumen with hyalinization, reduplication of the capillary basement membrane, deposition of extracellular matrix (ECM) and advanced glycation end-products (AGEs) within the media of the arterioles and arterial wall, a greater synthesis of pro-inflammatory cytokines and reactive oxygen species, inhibition of cell growth and proliferation, and DNA damage] [5] [6] [7] [8] [9] [10] .
The last decade has seen the development of new-generation PD solutions with a neutral pH and bicarbonate/lactate buffers [11] [12] [13] , and alternative osmotic agents such as amino acids, polypeptides and polyglucose (icodextrin) solutions are now available, but glucose remains the most widely used osmotic agent in PD for the time being. Although it is relatively safe, effective, readily metabolized and inexpensive, long-term exposure of the peritoneal tissues and cells to high concentrations of glucose can adversely affect peritoneal membrane and mesothelial cell integrity [14] .
Mesothelial cells are arranged in a single layer in the peritoneum. They are biochemically active and capable of synthesizing and secreting glycosaminoglycans and surfactant to prevent friction and the formation of adhesions between adjacent parietal and visceral surfaces [15] . They also regulate peritoneal inflammation and tissue remodelling by secreting inflammatory mediators, chemokines, growth factors and ECM components [16] [17] [18] .
Morphologically, mesothelial cells resemble epithelial cells and share many of the latter's characteristics (e.g. surface microvilli, apical/basal polarity, cytokeratins and junctional complexes), and long-term exposure to PD fluids can cause morphological and functional changes resembling epithelial-tomesenchymal transition (EMT) [19] [20] [21] , and consequently termed mesothelial-to-mesenchymal transition (MMT) [22] . It has been demonstrated that, soon after a PD session has begun, mesothelial cells gradually lose their epithelial phenotype [E-cadherin (E-CAD) and cytokeratins] and acquire fibroblastlike features (fibronectin, collagen I and migratory capacity) [19] . This leads to peritoneal fibrosis, which is the first cause of ultrafiltration failure and associated with a high risk of sclerosing encapsulating peritonitis [23, 24] .
We hypothesize that heparanase (HPSE)-an endoglycosidase that cleaves heparan sulfate (HS) chains, participates in extracellular remodelling [25] and is largely involved in renal cell EMT [26] [27] [28] [29] -could have an important role in MMT. Hence, this study assesses the contribution of HPSE in glucoseinduced MMT, and the effect of HPSE inhibition with a recently available agent (SST0001), in terms of minimizing the risk of fibrosis-related technical failures of PD.
M A T E R I A L S A N D M E T H O D S

Cell culture and treatments
Rat peritoneal mesothelial cells (RPMCs) were obtained from the peritoneal wall of male Wistar rats using a standard trypsin/ethylene diamine tetra-acetic acid (EDTA) digestion method. Briefly, the excised peritoneal flap was stretched on a sterile culture plate, and phosphate-buffered saline (PBS) containing 0.25% trypsin and 1 mmol/L EDTA was placed on the tissue for 15 min. The fluid retrieved was centrifuged at 1000 rpm for 5 min after adding Medium 199 containing 10% fetal bovine serum, 3.3 nM epidermal growth factor, 400 nM hydrocortisone, 3.87 lg/L selenium acid, 870 nM insulin and 20 mM HEPES. RPMC, identified from their cobblestone appearance, were obtained from three male rats weighing 450-500 g (18-20 weeks), pooled together and maintained in the same medium containing 100 U/mL penicillin and 100 lg/mL streptomycin in 5% CO 2 at 37 C. These RPMC were used between passages 3 and 6. The cells were grown to sub-confluence in standard medium, serum starved for 24 h, then treated with high glucose (HG) solutions (50, 100 and 200 mM) with or without SST0001 (10, 50, 100 and 200 ug/mL, corresponding to 0.5, 2.5, 5 and 10 mM). The detailed schedule of our in vitro model is shown in Figure 1 . HPSE and MMT markers were measured at 6 days because time-course experiments had demonstrated that the expression of the main MMT markers and vascular endothelial growth factor (VEGF) was strongest at this time-point (Supplementary Figure S1) .
Mannitol (200 mM) was used for osmotic control purposes (Supplementary Figure S2) . To assess the effect of PD solutions, the mesothelial cells were treated with an HG solution for PD (Physioneal 35 Glucose 3.86% w/v/38.6 mg/mL solution, Baxter) in a ratio of 1:3 with the culture medium according to the schedule in Figure 1 . The pH of the final solution was 7.4.
The experimental protocol and the procedures were completed with the approval of the Animal Ethics Committee of the University of Padova.
Viability assay
Mesothelial cells were plated on 96-well plates. Cell viability was ascertained 1, 3, 5 and 6 days after the various treatments (HG, 200 mM mannitol, 200 lg/mL SST0001 and PD solution), using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay
(Promega), according to the manufacturer's protocol. Briefly, 20 lL of reagent were added to each well, the plate was incubated for 3 h at 37 C, then the absorbance was measured at 490 nm. The experiment was performed twice in 6-fold.
Gene expression analysis
Total RNA was extracted from cell monolayers using the Trizol reagent (Invitrogen), according to the manufacturer's instructions. Yield and purity were checked using Nanodrop (EuroClone), and total RNA from each sample was reverse-transcribed into cDNA using SuperScript II Reverse Transcriptase (Invitrogen). Real-time PCR was performed on an ABI-Prism 7500 using Power SYBR Green Master Mix 2X (Applied Biosystems). The comparative Ct method (DDCt) was used to quantify gene expression, and the relative quantification was calculated as 2
ÀDDCt
. The presence of non-specific amplification products was excluded by melting curve analysis. The primers used are listed in Table 1 .
Western blotting
Cells were lysed in 50 mM Tris-HCl, pH 5.0, 150 mM NaCl, 0.5% Triton X-100 with Complete Protease Inhibitor Mixture (Roche Applied Science). Briefly, equal amounts of proteins were treated in reducing sample buffer and denatured for 10 min at 100 C. Protein samples were then resolved in 10% SDS-PAGE and electrotransferred to nitrocellulose membranes. Non-specific binding was blocked for 1 h at room temperature with non-fat milk (5%) in TBST buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.1% Tween 20). Membranes were exposed to primary antibodies directed against GAPDH and VEGF (Santa Cruz) overnight at 4 C and incubated with a secondary peroxidaseconjugated antibody for 1 h at room temperature. The signal was detected with SuperSignals West Pico Chemiluminescent substrate solution (Pierce) according to the manufacturer's instructions, and captured with a Kodak Image Station 2000R.
Immunofluorescence
Mesothelial cells were seeded in 22-mm glass dishes, cultured to sub-confluence and treated as described previously for the analysis of a-smooth muscle actin (a-SMA), vimentin (VIM), fibronectin (FN), E-CAD and filamentous actin (Factin). Cells were fixed in 4% paraformaldehyde and permeabilized, then incubated overnight at 4 C with the primary antibodies [a-SMA from Sigma Aldrich; VIM, FN, E-CAD, b-catenin (b-CAT) from Santa Cruz] in PBS with 1% bovine serum albumin (BSA), and then washed three times for 5 min with PBS before incubation for 1 h at 37 C with the secondary antibody (Alexa fluor 488 for E-CAD, a-SMA, FN and b-CAT; Alexa fluor 633 for VIM; Invitrogen), again in PBS with 1% BSA. For F-actin staining, cells were incubated with tetramethylrhodamineconjugated phalloidin (Sigma) for 20 min at room temperature. 
Transepithelial resistance and albumin permeability
Primary rat mesothelial cells (5 Â 10 4 cells/cm 2 ) were seeded and cultured on a polyester filter (0.4-lm pore size; Transwell, 12-well type, Millipore), using complete medium. The inner and outer chambers were filled with 0.5 and 1.5 mL of the culture medium, respectively, and the culture medium was replaced every 3 days.
Transepithelial resistance (TER) was measured daily using a Millicell-ERS ohmmeter with electrodes (Millipore) inserted on both sides of the filter. The alternating current applied between the electrodes was within 6 20 lA at a frequency of 12.5 Hz. The resistance of the monolayer was multiplied by the effective surface area to obtain the electrical resistance of the monolayer (X cm 2 ). The background TER of the blank Transwell filter was subtracted from the TER of the cell monolayer. Once stable resistances had been obtained, different culture media (control, SST0001, HG) were tested, taking the measurements 24 h after adding the test solutions.
The permeability of the mesothelial monolayer was recorded after stable resistances had been obtained. Evans blue-labelled albumin was added to the inner chamber of the Transwell at a final concentration of 0.5 mg/mL. Samples were collected at 24 h and colour changes were measured spectrophotometrically at 610 nm. The results are expressed as the percentage change in albumin permeability with respect to control cells.
Statistical analysis
Real-time PCR data were calculated with the Rest2009 software. Differences in the experimental comparisons were analysed using Student's t test. A P 0.05 was considered significant for all tests.
R E S U L T S HG and PD solutions up-regulated HPSE expression in rat mesothelial cells
To test whether HG solutions induced HPSE hyperexpression in mesothelial cells, real-time PCR was used to measure mRNA levels in cells cultured for 6 days with different glucose concentrations (50, 100 and 200 mM).
As shown in Figure 2 , under HG conditions (200 mM) the cells had a higher HPSE gene expression than controls (P < 0.01). HPSE was likewise up-regulated in cells treated with the 3.86% glucose PD solution. To ascertain the role of HPSE in the process of MMT, mesothelial cells were treated with an HG (200 mM) solution for the same number of days with or without the addition to in the culture media of a specific HPSE inhibitor (SST0001) in various concentrations (10, 50, 100 or 200 lg/mL) on day 3 (T3). Real-time PCR demonstrated that SST0001 inhibited the pro-fibrotic effects of the HG solution (Figure 3 ). This inhibitory effect of SST0001 was also apparent when it was administered at T0 (Supplementary Figure S3) , but the agent was added at T3 in some experiments in order to measure its ability to mitigate the already activated pro-fibrotic machinery. The strongest inhibitory effect was seen for SST0001 at 200 lg/mL (10 mM).
The same inhibitory effects were obtained using Suramin [31] , another HPSE inhibitor (Supplementary Figure S4) , thus confirming our main hypothesis.
Immunofluorescence confirmed the MMT induced by HG concentrations at protein level, and the role of HPSE in this process
Immunofluorescence (IF) was used to confirm the ability of HG solutions to enhance protein-level MMT markers, and to examine the contribution of HPSE to this effect.
Consistently with their gene expression, the HG solution raised the protein levels of a-SMA, VIM, FN and b-catenin after 6 days of culture, and adding SST0001 (on day 3) significantly reduced the MMT (Figure 4) .
Taken together, these data confirm that HG concentrations induce MMT, and HPSE has a pivotal regulatory role in this process.
IF thus confirmed that HG concentrations affected the distribution of E-CAD, which switched from the membrane to the cytoplasm, prompting a change in cytoskeletal structure with a reduction in junctional actin and an increase in stress fibres ( Figure 5A ). Image analysis also showed significantly Here again, treatment with SST0001 restored the epithelial phenotype with a significant reduction in the stress fibres and an enhanced E-CAD and F-actin co-localization ( Figure 5B ).
HPSE inhibition reversed the glucose-induced increase in VEGF levels
VEGF is a profibrotic factor that regulates peritoneal neoangiogenesis in long-term PD patients, so our in vitro model was also used to measure its mRNA (by real-time PCR) and protein (by western blotting) levels. As shown in Figure 6 , the HG solution up-regulated VEGF, and the HPSE inhibitor hindered this effect ( Figure 6 ). This goes to show (in vitro at least) that using HG PD solutions can exacerbate neoangiogenesis, impairing the effects of dialysis, and inhibiting HPSE might plausibly help to minimize this effect.
Mesothelial cell viability is affected by HG concentrations
We found that long-term exposure of mesothelial cells to HG concentrations significantly reduced their viability. Administering mannitol had the same effect. Treatment with SST0001 did not affect cell viability in controls or HG-treated cells (Figure 7) . We surmise that the HG-induced decline in cell viability is an osmotic event, and that HPSE inhibition had no significant influence on this process.
Mesothelial layer functional tests
TER and permeability to albumin were measured in our in vitro model to see whether HPSE inhibition could also influence the mesothelial layer ultrafiltration function.
HG concentrations reduced the TER of the mesothelial cell layer ( Figure 8A ) and significantly increased its albumin permeability ( Figure 8B ). After adding SST001, the layer's TER returned to the baseline value ( Figure 8A ), and its albumin permeability was significantly reduced ( Figure 8B ).
PD solutions induced MMT (like HG solutions)
Mesothelial cells were exposed to a PD solution (PHYSIONEAL 35 Glucose 3.86% w/v solution, Baxter) following the schedule in Figure 1 to see whether a PD solution with an HG content had the same pro-fibrotic effects as an HG solution. As expected, the PD solution significantly up-regulated the gene expression of MMT markers a-SMA, TGF-b, VIM and VEGF, and HPSE inhibition with SST0001 completely reversed the effects (Figure 9 ). The PD solution also reduced mesothelial cell viability, and this effect was not reduced by SST0001 (Supplementary Figure S5) .
D I S C U S S I O N
Long-term contact of the peritoneal membrane with dialysis fluids containing high concentrations of glucose as the osmotic agent profoundly alters the mesothelial cells, simple squamous cells forming most of the surface area across which molecular exchange occurs during PD [32] [33] [34] .
It is common knowledge that the glucose in PD solutions can contribute to peritoneal damage and fibrosis both directly, by inducing EMT, and indirectly, by enhancing the level of glucose degradation products (GDPs; e.g. methylglyoxal, glyoxal, formaldehyde and 3-deoxyglucosone) released during sterilization with heat and storage [35, 36] . GDPs can significantly increase the expression of several well-known EMT and neoangiogenetic markers such as TGF-b, collagen 1, matrix metallopeptidase 2 and VEGF [37] [38] [39] . They are also precursors of AGEs, formed by non-enzymatic glycation between reducing sugars and proteins, lipids and nucleic acids, which act as EMT inducers [40] [41] [42] [43] . AGEs accumulate in the peritoneum of PD patients depending on the duration of dialysis [44] . 
| | | | | | | | |
It is therefore undeniable that controlling the EMT of mesothelial cells induced by HG solutions is a great challenge in nephrology, and new activators/regulators of this pathological pathway need to be identified in order to devise new therapeutic strategies capable of delaying the progression of peritoneal functional failure and avoiding the need to switch to HD.
Several biological/cellular elements could be identified as targets of innovative anti-fibrotic agents, and HPSE-an enzyme extensively studied by our research group-seems to be a good candidate. HPSE is an endo-b-D-glucuronidase that cleaves HS side chains at a limited number of sites, participating in ECM degradation and remodelling [45, 46] . ECM degradation can trigger the release of HS-bound growth factors and cytokines, prompting the proliferation of endothelial cells and fibroblasts, and degradation of the basement membrane, with a consequent increase in cell motility [47] . Judging from its biochemical profile, this enzyme has a strong profibrotic role and is directly involved in the EMT of renal tubular cells [26] [27] [28] [29] .
As expected, our data confirmed the important contribution of HPSE to the EMT of mesothelial cells exposed to HG solutions. Six days of stimulation with an HG (200 mM) solution significantly raised both gene and protein levels of MMT markers (a-SMA, VIM and TGF-b) and down-regulated epithelial markers such as E-CAD. The HG treatment also significantly up-regulated VEGF (a neoangiogenetic factor), confirming previous findings [48, 49] . As amply reported, high VEGF levels increase peritoneal vasculature permeability, small solute transport, glucose adsorption and the dissipation of the glucosedriven osmotic pressure, leading to ultrafiltration failure [50, 51] .
Several researchers have suggested that inhibiting HPSE with various agents could be a novel way to minimize fibrosis in several tissues and organs (especially the kidney) [52, 53] . We previously demonstrated that HPSE inhibition with sulodexide-a highly purified mixture of glycosaminoglycans composed of low-molecular-weight heparin (LMWH) and dermatan sulfate-can effectively inhibit EMT in renal tubular epithelial cells treated with very high doses of everolimus, an immunosuppressant and anticancer agent widely used in organ transplant medicine and oncology [54, 55] . Other groups have also suggested that LMWH could have beneficial effects on peritoneal fibrosis and neoangiogenesis during PD [56] [57] [58] . Unfortunately, these molecules have anticoagulant properties that limit their use in PD because their intra-peritoneal administration could give rise to bleeding complications.
On the other hand, the newly available SST0001, with its marked anti-HPSE activity and no anticoagulant effect, seems a safer proposal for use in PD. SST0001 was developed by chemically modifying porcine mucosal heparin, giving rise to a molecule that is 100% N-acetylated and 25% glycol split [59] [60] [61] [62] .
The use of several biomolecular techniques in our study confirmed the anti-EMT potential of SST0001 in mesothelial cells and its anti-fibrotic effects. Increasing concentrations (10, 50, 100 and 200 mg/mL) of this agent proportionally modulated the expression of MMT markers (a-SMA, VIM, TGF-b and VEGF), leading us to conclude that MMT inhibition by SST0001 is linked to a blockade of the enzymatic activity of HPSE.
Administered before (T0) or 3 h after (T3) an HG solution, SST0001 was able to reverse the MMT process induced in mesothelial cells. This may mean that SST0001 could be beneficial not only to prevent, but also to treat early MMT-induced peritoneal fibrosis.
These findings were validated by the results of functional tests. HPSE inhibition by SST0001 was also able to restore TER and albumin permeability to their basal levels after exposure to the HG solution. Although encouraging, our findings were obtained in vitro and naturally need to be reproduced in a more complex in vivo system, and then in clinical studies to confirm the clinical utility of inhibiting HPSE and to assess the safety of such a treatment before it can be adopted in day-to-day clinical practice.
Although no final clinical conclusions can be drawn from our findings, this study is the first (to the best of our knowledge) to demonstrate that HPSE is involved in the profibrotic peritoneal machinery. If our findings are confirmed, the specific inhibition of this enzyme could represent a novel therapeutic approach to minimize fibrosis and extend the use of PD.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxford journals.org. . Expression values were normalized to GAPDH. Mean 6 standard deviation (error bars) of three separate experiments performed in triplicate. *P < 0.05, **P < 0.01 versus CTR; # P < 0.05, ## P < 0.01 versus PD sol.
